Core Insights - DBV Technologies will participate in the Guggenheim 2 Annual Healthcare Innovation Conference on November 11, where CEO Daniel Tassé will engage in a fireside chat [1] - A live webcast of the event will be available, along with an archived replay for 90 days [2] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [3] - The company is investigating its proprietary VIASKIN® patch technology, which aims to treat food allergies through epicutaneous immunotherapy (EPIT) [3] - The VIASKIN® patch introduces microgram amounts of biologically active compounds to the immune system via intact skin, aiming to desensitize individuals to allergens [3] - Current clinical trials include the VIASKIN Peanut for peanut allergic toddlers aged 1 to 3 years and children aged 4 to 7 years [3] - DBV Technologies is headquartered in Châtillon, France, with operations in Warren, NJ, and its shares are traded on Euronext Paris and the Nasdaq Capital Market [4]